|
1
|
No authors listed. Leuprolide versus
diethylstilbestrol for metastatic prostate cancer. The Leuprolide
Study Group. N Engl J Med. 311:1281–1286. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gittes RF: Carcinoma of the prostate. N
Engl J Med. 324:236–245. 1991. View Article : Google Scholar
|
|
3
|
Wirth MP: Hormone-refractory prostate
cancer: what have we learned? BJU Int. 100(Suppl 2): 56–59. 2007.
View Article : Google Scholar
|
|
4
|
Tashiro K, Tada H, Heilker R, Shirozu M,
Nakano T and Honjo T: Signal sequence trap: a cloning strategy for
secreted proteins and type I membrane proteins. Science.
261:600–603. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bleul CC, Fuhlbrigge RC, Casasnovas JM,
Aiuti A and Springer TA: A highly efficacious lymphocyte
chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med.
184:1101–1109. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wells TN, Power CA, Lusti-Narasimhan M, et
al: Selectivity and antagonism of chemokine receptors. J Leukoc
Biol. 59:53–60. 1996.PubMed/NCBI
|
|
7
|
Zlotnik A: Chemokines and cancer. Int J
Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furusato B, Mohamed A, Uhlen M and Rhim
JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar
|
|
10
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akashi T, Koizumi K, Tsuneyama K, Saiki I,
Takano Y and Fuse H: Chemokine receptor CXCR4 expression and
prognosis in patients with metastatic prostate cancer. Cancer Sci.
99:539–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Darash-Yahana M, Pikarsky E, Abramovitch
R, et al: Role of high expression levels of CXCR4 in tumor growth,
vascularization, and metastasis. FASEB J. 18:1240–1242.
2004.PubMed/NCBI
|
|
13
|
Smart EJ and Anderson RG: Alterations in
membrane cholesterol that affect structure and function of
caveolae. Methods Enzymol. 353:131–139. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kucia M, Reca R, Miekus K, et al:
Trafficking of normal stem cells and metastasis of cancer stem
cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4
axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Wang J, Sun Y, et al: Diverse
signaling pathways through the SDF-1/CXCR4 chemokine axis in
prostate cancer cell lines leads to altered patterns of cytokine
secretion and angiogenesis. Cell Signal. 17:1578–1592. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chinni SR, Sivalogan S, Dong Z, et al:
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in
prostate cancer cells: the role of bone microenvironment-associated
CXCL12. Prostate. 66:32–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh S, Singh UP, Grizzle WE and Lillard
JW Jr: CXCL12-CXCR4 interactions modulate prostate cancer cell
migration, metalloproteinase expression and invasion. Lab Invest.
84:1666–1676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kukreja P, Abdel-Mageed AB, Mondal D, Liu
K and Agrawal KC: Up-regulation of CXCR4 expression in PC-3 cells
by stromal-derived factor-1alpha (CXCL12) increases endothelial
adhesion and transendothelial migration: role of MEK/ERK signaling
pathway-dependent NF-kappaB activation. Cancer Res. 65:9891–9898.
2005. View Article : Google Scholar
|
|
19
|
Okera M, Bae K, Bernstein E, et al:
Evaluation of nuclear factor kappaB and chemokine receptor CXCR4
co-expression in patients with prostate cancer in the Radiation
Therapy Oncology Group (RTOG) 8610. BJU Int. 108:E51–E58. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Diao X, Sun J and Chen Z:
Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate
cancer cell line. Cell Biol Int. 35:897–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leelawat K, Leelawat S, Narong S and
Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4
induced cholangiocarcinoma cell invasion. World J Gastroenterol.
13:1561–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Libura J, Drukala J, Majka M, et al:
CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and
regulates locomotion, chemotaxis, and adhesion. Blood.
100:2597–2606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mori T, Doi R, Koizumi M, et al: CXCR4
antagonist inhibits stromal cell-derived factor 1-induced migration
and invasion of human pancreatic cancer. Mol Cancer Ther. 3:29–37.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong X, Jiang F, Kalkanis SN, et al: SDF-1
and CXCR4 are up-regulated by VEGF and contribute to glioma cell
invasion. Cancer Lett. 236:39–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gilbert DC, Chandler I, McIntyre A, et al:
Clinical and biological significance of CXCL12 and CXCR4 expression
in adult testes and germ cell tumours of adults and adolescents. J
Pathol. 217:94–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kijima T, Maulik G, Ma PC, et al:
Regulation of cellular proliferation, cytoskeletal function, and
signal transduction through CXCR4 and c-Kit in small cell lung
cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI
|
|
27
|
Li JK, Yu L, Shen Y, Zhou LS, Wang YC and
Zhang JH: Inhibition of CXCR4 activity with AMD3100 decreases
invasion of human colorectal cancer cells in vitro. World J
Gastroenterol. 14:2308–2313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kajiyama H, Shibata K, Terauchi M, Ino K,
Nawa A and Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the
enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int
J Cancer. 122:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sehgal A, Keener C, Boynton AL, Warrick J
and Murphy GP: CXCR-4, a chemokine receptor, is overexpressed in
and required for proliferation of glioblastoma tumor cells. J Surg
Oncol. 69:99–104. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sehgal A, Ricks S, Boynton AL, Warrick J
and Murphy GP: Molecular characterization of CXCR-4: a potential
brain tumor-associated gene. J Surg Oncol. 69:239–248. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uchida D, Onoue T, Tomizuka Y, et al:
Involvement of an autocrine stromal cell derived factor-1/CXCR4
system on the distant metastasis of human oral squamous cell
carcinoma. Mol Cancer Res. 5:685–694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kreisberg JI, Malik SN, Prihoda TJ, et al:
Phosphorylation of Akt (Ser473) is an excellent predictor of poor
clinical outcome in prostate cancer. Cancer Res. 64:5232–5236.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ayala G, Thompson T, Yang G, et al: High
levels of phosphorylated form of Akt-1 in prostate cancer and
non-neoplastic prostate tissues are strong predictors of
biochemical recurrence. Clin Cancer Res. 10:6572–6578. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rubin JB, Kung AL, Klein RS, et al: A
small-molecule antagonist of CXCR4 inhibits intracranial growth of
primary brain tumors. Proc Natl Acad Sci USA. 100:13513–13518.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Falco V, Guarino V, Avilla E, et al:
Biological role and potential therapeutic targeting of the
chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer
Res. 67:11821–11829. 2007.PubMed/NCBI
|
|
36
|
Yoon Y, Liang Z, Zhang X, et al: CXC
chemokine receptor-4 antagonist blocks both growth of primary tumor
and metastasis of head and neck cancer in xenograft mouse models.
Cancer Res. 67:7518–7524. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Orimo A, Gupta PB, Sgroi DC, et al:
Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
secretion. Cell. 121:335–348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hendrix CW, Collier AC, Lederman MM, et
al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a
selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir
Immune Defic Syndr. 37:1253–1262. 2004. View Article : Google Scholar : PubMed/NCBI
|
